AGIO
Agios Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.10
−0.09%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.3x
Market Cap
$1.98B
MomentumView details →
1D Return
−0.09%
YTD Return
+21.93%
RSI (14)
45.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.3x
Market Cap
$1.98B
RSI (14)
45.7
MomentumView details →
1D Return
−0.09%
YTD Return
+21.93%
SummaryUpdated Jun 1, 2026
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company founded in 2007 and headquartered in Cambridge, Massachusetts. The company went public in July 2013 and specializes in discovering and developing medicines targeting cellular metabolism and adjacent areas of biology. Agios has successfully commercialized its first product, PYRUKYND (mitapivat), for treating rare blood disorders, and maintains a robust pipeline of investigational therapies for various hemolytic anemias and other metabolic conditions.
Similar companies
Latest newsMore news →
Assenagon Asset Management S.A. increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, acquiring 36,802 additional shares, according to a Form 13F filing.23d agoAgios Pharmaceuticals advanced AG-236 into Phase 2/3 development for polycythemia vera.36d agoAgios Pharmaceuticals licensed cevidoplenib for immune thrombocytopenia, diversifying its late-stage pipeline.36d ago